Gyan Chandra

Array ( [id] => 18389894 [patent_doc_number] => 20230158112 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-25 [patent_title] => Targeting gamma-delta T Cells in Obesity and Cachexia [patent_app_type] => utility [patent_app_number] => 17/929209 [patent_app_country] => US [patent_app_date] => 2022-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13488 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17929209 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18077381 [patent_doc_number] => 20220402993 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-22 [patent_title] => INSULIN-TRANSFERRIN FUSION PROTEIN AND ITS PRODRUG, PROINSULIN-TRANSFERRIN, FOR OVERCOMING INSULIN RESISTANCE [patent_app_type] => utility [patent_app_number] => 17/895638 [patent_app_country] => US [patent_app_date] => 2022-08-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10127 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17895638 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18413156 [patent_doc_number] => 11667689 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-06-06 [patent_title] => Insulin-Fc fusion proteins and methods of use to treat cancer [patent_app_type] => utility [patent_app_number] => 17/814285 [patent_app_country] => US [patent_app_date] => 2022-07-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 21873 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 145 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17814285 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20136225 [patent_doc_number] => 20250243269 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-07-31 [patent_title] => ANTI-FSH ANTIBODIES FOR NEURODEGENERATIVE DISEASES [patent_app_type] => utility [patent_app_number] => 18/290611 [patent_app_country] => US [patent_app_date] => 2022-07-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10477 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18290611 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18228934 [patent_doc_number] => 20230067928 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-02 [patent_title] => METHODS FOR PROGNOSING AND PREVENTING METASTATIC LIVER DISEASE [patent_app_type] => utility [patent_app_number] => 17/869948 [patent_app_country] => US [patent_app_date] => 2022-07-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22728 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17869948 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18251551 [patent_doc_number] => 20230078590 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-16 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED DIABETES AND RELATED DISORDERS [patent_app_type] => utility [patent_app_number] => 17/813383 [patent_app_country] => US [patent_app_date] => 2022-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10725 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17813383 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17958515 [patent_doc_number] => 20220339095 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-27 [patent_title] => METHODS FOR DELIVERING ETANERCEPT PREPARATIONS INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE [patent_app_type] => utility [patent_app_number] => 17/863322 [patent_app_country] => US [patent_app_date] => 2022-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23270 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17863322 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18177058 [patent_doc_number] => 20230037787 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-09 [patent_title] => METHODS AND COMPOSITIONS RELATING TO HOT-START, ONE-STEP, REVERSE TRANSCRIPTION-COUPLED PCR [patent_app_type] => utility [patent_app_number] => 17/862825 [patent_app_country] => US [patent_app_date] => 2022-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10484 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17862825 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19989638 [patent_doc_number] => 20250127860 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-04-24 [patent_title] => SEMAGLUTIDE DEPOT SYSTEMS AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/572577 [patent_app_country] => US [patent_app_date] => 2022-07-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14017 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18572577 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18427647 [patent_doc_number] => 11672848 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-06-13 [patent_title] => Method of eliciting a CD8+ cytotoxic response in hepatocellular carcinoma patients with a population of activated T cells [patent_app_type] => utility [patent_app_number] => 17/852623 [patent_app_country] => US [patent_app_date] => 2022-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 22 [patent_no_of_words] => 48796 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 127 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17852623 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18683928 [patent_doc_number] => 11779638 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-10 [patent_title] => Method of eliciting a CD8+ cytotoxic response in hepatocellular carcinoma patients with a population of activated T cells [patent_app_type] => utility [patent_app_number] => 17/853334 [patent_app_country] => US [patent_app_date] => 2022-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 22 [patent_no_of_words] => 48788 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 138 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17853334 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17958692 [patent_doc_number] => 20220339272 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-27 [patent_title] => PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (HCC) AND OTHER CANCERS [patent_app_type] => utility [patent_app_number] => 17/853344 [patent_app_country] => US [patent_app_date] => 2022-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48385 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17853344 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18159003 [patent_doc_number] => 20230025595 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-26 [patent_title] => Formulation and Method of Preparing Divalent Cation Charged Insulin for Oral Administration [patent_app_type] => utility [patent_app_number] => 17/849626 [patent_app_country] => US [patent_app_date] => 2022-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11407 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17849626 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18146769 [patent_doc_number] => 20230020626 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-19 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING OBESITY AND HYPERPHAGIA [patent_app_type] => utility [patent_app_number] => 17/848974 [patent_app_country] => US [patent_app_date] => 2022-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16172 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17848974 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20413067 [patent_doc_number] => 12496329 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-16 [patent_title] => Methods of using and compositions including an incretin analog [patent_app_type] => utility [patent_app_number] => 18/573779 [patent_app_country] => US [patent_app_date] => 2022-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18835 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 99 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18573779 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19923006 [patent_doc_number] => 12297277 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-13 [patent_title] => Anti-sortilin antibodies and methods of use thereof [patent_app_type] => utility [patent_app_number] => 17/836707 [patent_app_country] => US [patent_app_date] => 2022-06-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 71409 [patent_no_of_claims] => 53 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17836707 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20108283 [patent_doc_number] => 12358991 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-15 [patent_title] => Anti-Sortilin antibodies and methods of use thereof [patent_app_type] => utility [patent_app_number] => 17/836644 [patent_app_country] => US [patent_app_date] => 2022-06-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 71185 [patent_no_of_claims] => 52 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17836644 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20295009 [patent_doc_number] => 20250320252 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-10-16 [patent_title] => LONG-ACTING DUAL GIP/GLP-1 PEPTIDE CONJUGATES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/568244 [patent_app_country] => US [patent_app_date] => 2022-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 61856 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18568244 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19930405 [patent_doc_number] => 12303598 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-20 [patent_title] => Pharmaceutical composition comprising a GLP-1-agonist and methionine [patent_app_type] => utility [patent_app_number] => 17/747723 [patent_app_country] => US [patent_app_date] => 2022-05-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 2165 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17747723 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17830130 [patent_doc_number] => 20220267434 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-25 [patent_title] => Long-Acting Therapeutic Fusion Proteins [patent_app_type] => utility [patent_app_number] => 17/741126 [patent_app_country] => US [patent_app_date] => 2022-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10844 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17741126 [rel_patent_id] =>[rel_patent_doc_number] =>)